Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma - Takeaways - MDSpire
From the Journals

Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma

A cohort study showed that patients with melanoma who received BRAF or MEK inhibitor therapy commonly experienced hypertension and mild cardiac dysfunction, supporting baseline cardiotoxicity risk str...

  • By

  • Julia Cipriano

  • May 8, 2026

  • 4 min

Share

  • 1

    Nearly half of melanoma patients on BRAF/MEK inhibitors develop cardiac dysfunction.

  • 2

    Most cases are mild and not progressive.

  • 3

    Early assessment at 4 weeks is crucial.

  • 4

    Recommended monitoring includes blood pressure and echocardiography.

  • 5

    NT-proBNP levels are higher in patients with cardiac dysfunction.

  • 6

    There is a need for improved risk stratification methods.

Original Source(s)

Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma

  • by Julia Cipriano

  • May 8, 2026

Related Content

Most Decline Proactive Care Coordination

"Lack of effective communication across physicians is a health system problem."

Bereavement Tied to Higher Cardiovascular Risk

Acute post-loss period and pandemic conditions each amplified cardiovascular vulnerability in nationwide Swedish cohort study

Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

Frailty severity may identify older patients least likely to benefit—and potentially at higher risk—with invasive management